Cambridge, UK – The University of Cambridge is developing the world’s first vaccine designed entirely using artificial intelligence. This is a step described as potentially representing a significant shift in the field of vaccine development and the fight against infectious diseases.
Targeting multiple viruses
The project aims to produce a vaccine based on what is known as a “superantigen.”
This antigen is designed using artificial intelligence to train the immune system to recognize
a broad spectrum of viruses within a single family, rather than targeting only one virus.
According to the project’s developers, the vaccine is designed to potentially offer protection against all coronaviruses and their variants.
Furthermore, it provides protection against other animal viruses believed to be potential future pandemics.
The researchers believe this approach could represent a paradigm shift in prevention,
moving from traditional vaccines to “broad” vaccines that anticipate the emergence of new strains.
Promising preliminary results
Professor Jonathan Heeney, one of the project’s participants, said the primary goal is to “get ahead”
by developing vaccines capable of protecting humans from future pathogens before they emerge and spread.
Initial trials conducted on 39 volunteers showed the vaccine to be safe.
Meanwhile, a larger study involving approximately 200 people is currently underway to assess its efficacy and immune response.
The research team at Cambridge University is working to expand the project to
include the development of future vaccines against seasonal influenza and avian influenza.
Additionally, vaccines against other viruses, such as Ebola, are being developed as part of efforts to enhance global preparedness for future pandemics.
